肿瘤预防与治疗2025，Vol.38Issue(4)：273-279,7.DOI:10.3969/j.issn.1674-0904.2025.04.004
卵巢癌铂敏感性复发再次PARP抑制剂维持治疗的探索性研究:单中心临床经验分享
Exploratory Study on PARP Inhibitor Retreatment in Platinum-Sensitive Recurrent Ovarian Cancer:A Single-Center Clinical Experience
摘要
Abstract
Objective:To explore the feasibility and prog-nostic factors of poly(ADP-ribose)polymerase(PARP)in-hibitor retreatment in platinum-sensitive recurrent ovarian cancer.Methods:We retrospectively analyzed clinical records and prognostic outcomes of ovarian cancer patients who received two courses of PARP inhibitor maintenance therapy at our institution.Results:A total of 13 patients were enrolled,all of whom completed follow-up with a median follow-up time of 28 months.All enrolled patients had high-risk features for recurrence.Of these,84.6%(11/13)received PARP inhibitors as first-line maintenance therapy.The median progression-free survival for patients receiving initial PARP inhibitor maintenance therapy was 10 months(range:6～33 months).Eight patients(61.5%)demonstrated longer or equal progression-free sur-vival during the second PARP inhibitor maintenance therapy(2nd-PFS)compared to the first course(1st-PFS).Among the 8 patients with 2nd-PFS≥1st-PFS,6(75.0%)were BRCA wild-type,while 1(12.5%)harbored a BRCA mutation;4(50.0%)underwent secondary cytoreductive surgery(SCS)with R0 resection at recurrence,all achieving complete remis-sion(CR)before the second maintenance therapy;2(25.0%)were in partial remission(PR)pre-second maintenance and received combination therapy with antiangiogenic agents;the single BRCA-mutant patient achieved PR before the second ma-intenance therapy without switching maintenance agents.Conclusion:Patients with platinum-sensitive recurrent ovarian canc-er who achieve CR after primary treatment-particularly those attaining R0 status through SCS-may benefit from PARP inhibitor rechallenge or combination regimens incorporating antiangiogenic agents,potentially improving long-term outcomes.关键词
卵巢癌/聚二磷酸腺苷核糖聚合酶(PARP)抑制剂/维持治疗/铂敏感复发/二次肿瘤细胞减灭术Key words
Ovarian cancer/PARP inhibitor/Maintenance treatment/Platinum-sensitive recurrence/Secondary cytore-ductive surgery分类
医药卫生引用本文复制引用
郑静,张杰,彭立平,张灿,史洵玮,王登凤,张国楠..卵巢癌铂敏感性复发再次PARP抑制剂维持治疗的探索性研究:单中心临床经验分享[J].肿瘤预防与治疗,2025,38(4):273-279,7.基金项目
This study was supported by grants from University of Electronic Science and Technology of China(No.ZYGX2022J024). 电子科技大学中央高校基本科研业务费项目(编号:ZYGX2022J024) （No.ZYGX2022J024）
